Global’s September 2025 Stock Picks That May Be Priced Below Fair Value

As global markets navigate a period marked by expectations of interest rate cuts and the ongoing enthusiasm for artificial intelligence, major U.S. stock indexes have reached new record highs, buoyed by optimistic economic indicators. Amid this landscape of fluctuating inflation rates and evolving monetary policies, identifying stocks that may be priced below their fair value can be a strategic approach for investors looking to capitalize on potential market inefficiencies.
“
“
“
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Truecaller (OM:TRUE B) |
SEK43.04 |
SEK85.80 |
49.8% |
|
Suzhou Alton Electrical & Mechanical Industry (SZSE:301187) |
CN¥29.37 |
CN¥58.18 |
49.5% |
|
Nanjing COSMOS Chemical (SZSE:300856) |
CN¥14.23 |
CN¥28.38 |
49.9% |
|
Kolmar Korea (KOSE:A161890) |
₩78400.00 |
₩154923.17 |
49.4% |
|
HL Holdings (KOSE:A060980) |
₩41500.00 |
₩82434.95 |
49.7% |
|
FP Partner (TSE:7388) |
¥2228.00 |
¥4425.25 |
49.7% |
|
Faraday Technology (TWSE:3035) |
NT$150.50 |
NT$300.04 |
49.8% |
|
Digital Workforce Services Oyj (HLSE:DWF) |
€3.41 |
€6.82 |
50% |
|
Atea (OB:ATEA) |
NOK142.00 |
NOK280.67 |
49.4% |
|
Anhui Ronds Science & Technology (SHSE:688768) |
CN¥49.18 |
CN¥97.17 |
49.4% |
“
“
We’re going to check out a few of the best picks from our screener tool.
“
“
Overview: Turkcell Iletisim Hizmetleri A.S., along with its subsidiaries, offers converged telecommunication and technology services in Turkey, Belarus, the Turkish Republic of Northern Cyprus, and the Netherlands, with a market cap of TRY204.02 billion.
“
Operations: The company’s revenue is primarily derived from its Turkcell Turkey segment, which accounts for TRY153.66 billion, and its Techfin segment, contributing TRY9.88 billion.
“
“
Estimated Discount To Fair Value: 20.6%
“
Turkcell Iletisim Hizmetleri appears undervalued, trading at TRY 93.65, below its estimated fair value of TRY 117.88. Despite a drop in profit margins from 13.7% to 7%, the company’s revenue and earnings are forecast to grow significantly above market rates, at 27.2% and over 52% annually, respectively. Recent earnings showed robust sales growth but a slight dip in six-month net income year-over-year, reflecting mixed financial health amidst strong cash flow potential.
“
“
“
“
Overview: Acrobiosystems Co., Ltd. develops and manufactures recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies as well as scientific research institutions, with a market cap of CN¥9.71 billion.
Credit: Source link



